8 results on '"Pane, Marco"'
Search Results
2. Assessment of shelf-life and metabolic viability of a multi-strain synbiotic using standard and innovative enumeration technologies.
- Author
-
Visciglia, Annalisa, Allesina, Serena, Amoruso, Angela, De Prisco, Annachiara, Dhir, Raja, Bron, Peter A., and Pane, Marco
- Abstract
The number of live bacterial cells is the most used parameter to assess the quality of finished probiotic products. Plate counting (PC) is the standard method in industry to enumerate cells. Application of PC implies critical aspects related to the selection of optimal nutrient media and growth conditions and underestimation of viable but not cultivable (VBNC) cells. Flow-cytometry (FC) is a culture-independent methodology having the potential to selectively enumerate live, damaged, and dead cells representing a powerful tool for in-depth monitoring of probiotic products. We monitored the shelf life of a clinical batch of a synbiotic composition PDS-08 targeting the pediatric population by means of PC and FC according to International Conference on Harmonization (ICH) pharma guidelines testing the Arrhenius model as predictive tool; PC enumeration revealed higher destruction rate than FC suggesting a faster reduction in cultivability than membrane integrity and thus a possible shift of the bacteria into a VBNC status. PDS-08 maintained acidification capability over time, when re-suspended in nutrient medium, even in samples tested sub-optimally for CFU detection (below 1 billion cells/dose). Due to similar kinetics described by the study of metabolic activity and membrane integrity, FC might be suggested as a valid tool for the study of functional stability of a probiotic product. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence.
- Author
-
Magistrelli, Luca, Amoruso, Angela, Mogna, Luca, Graziano, Teresa, Cantello, Roberto, Pane, Marco, and Comi, Cristoforo
- Subjects
PARKINSON'S disease ,KLEBSIELLA pneumoniae ,CYTOKINES ,ESCHERICHIA coli ,OXIDATIVE stress - Abstract
Background: Parkinson's disease (PD) is characterized by loss of dopaminergic neurons and intraneuronal accumulation of alpha-synuclein, both in the basal ganglia and in peripheral sites, such as the gut. Peripheral immune activation and reactive oxygen species (ROS) production are important pathogenetic features of PD. In this context, the present study focused on the assessment of in vitro effects of probiotic bacterial strains in PBMCs isolated from PD patients vs. healthy controls. Methods: 40 PD patients and 40 matched controls have been enrolled. Peripheral blood mononuclear cells (PBMCs) were isolated and co-cultured with a selection of probiotics microorganisms belonging to the lactobacillus and bifidobacterium genus. In vitro release of the major pro- (Tumor Necrosis Factor-alpha and Interleukin-17A and 6) and anti-inflammatory (Interleukin 4 and 10) cytokines by PBMCs, as well as the production of ROS was investigated. Furthermore, we assessed the ability of probiotics to influence membrane integrity, antagonize the growth of potential pathogen bacteria, such as Escherichia coli and Klebsiella pneumoniae and encode tyrosine decarboxylase genes (tdc). Results: All probiotic strains were able to inhibit inflammatory cytokines and ROS production in both patients and controls. The most striking results were obtained in PD subjects with L. salivarius LS01 and L. acidophilus which significantly reduced pro-inflammatory and increased the anti-inflammatory cytokines (p < 0.05). Furthermore, most strains determined restoration of membrane integrity and inhibition of E. coli and K. pneumoniae. Finally, we also showed that all the strains do not carry tdc gene, which is known to decrease levodopa bioavailability in PD patients under treatment. Conclusions: Probiotics exert promising in vitro results in decreasing pro-inflammatory cytokines, oxidative stress and potentially pathogenic bacterial overgrowth. In vivo longitudinal data are mandatory to support the use of bacteriotherapy in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Delivery of Metabolically Neuroactive Probiotics to the Human Gut.
- Author
-
Bron, Peter A., Catalayud, Marta, Marzorati, Massimo, Pane, Marco, Kartal, Ece, Dhir, Raja, and Reid, Gregor
- Subjects
VITAMIN B12 ,SMALL intestine ,HUMAN microbiota ,GASTROINTESTINAL system ,PROBIOTICS ,ANXIETY ,METABOLOMICS - Abstract
The human microbiome is a rich factory for metabolite production and emerging data has led to the concept that orally administered microbial strains can synthesize metabolites with neuroactive potential. Recent research from ex vivo and murine models suggests translational potential for microbes to regulate anxiety and depression through the gut-brain axis. However, so far, less emphasis has been placed on the selection of specific microbial strains known to produce the required key metabolites and the formulation in which microbial compositions are delivered to the gut. Here, we describe a double-capsule technology to deliver high numbers of metabolically active cells derived from the 24-strain probiotic product SH-DS01 to the gastrointestinal tract, including the small intestine, where immune responses and adsorption of metabolites into the bloodstream occur. Based on its genome sequence, Limosilactobacillus reuteri SD-LRE2-IT was predicted to have the genetic capacity to de novo produce a specific metabolite of interest to brain health, vitamin B12, which could be confirmed in vitro. Taken together, our data conceptualizes the importance of rationally defined microbial strain characterization based on genomics and metabolomics data, combined with carefully designed capsule technology for delivery of live cells and concomitant functionality in and beyond the gut ecosystem. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. In-process real-time probiotic phenotypic strain identity tracking: The use of Fourier transform infrared spectroscopy
- Author
-
Francesca Deidda, Miriam Cordovana, Nicole Bozzi Cionci, Teresa Graziano, Diana Di Gioia, Marco Pane, Deidda, Francesca, Cordovana, Miriam, Bozzi Cionci, Nicole, Graziano, Teresa, Di Gioia, Diana, and Pane, Marco
- Subjects
Microbiology (medical) ,FTIR spectroscopy ,large-scale production ,Lactiplantibacillus plantarum ,strain typing ,Microbiology ,IR Biotyper® ,probiotic - Abstract
Probiotic bacteria, capable of conferring benefits to the host, can present challenges in design, development, scale-up, manufacturing, commercialization, and life cycle management. Strain identification is one of the main quality parameters; nevertheless, this task can be challenging since established methodologies can lack resolution at the strain level for some microorganisms and\or are labor-intensive and time-consuming. Fourier transform infrared spectroscopy (FTIRS) has been largely used for the investigation of pathogenic species in the clinical field, whereas only recently has been proposed for the identification of probiotic strains. Within the probiotic industrial production, bacterial strains can be subjected to stressful conditions that may affect genomic and phenotypic characteristics; therefore, real-time monitoring of all the sequential growth steps is requested. Considering the fast, low-cost, and high-throughput features, FTIRS is an innovative and functional technology for typing probiotic strains from bench-top experiments to large-scale industrial production, allowing the monitoring of stability and identity of probiotic strains. In this study, the discriminatory power of FTIRS was assessed for four Lactiplantibacillus plantarum probiotic strains grown under different conditions, including temperatures (30 and 37°C) and medium (broth and agar), after consecutive sub-culturing steps. A comparison between the generated spectra with pulsed-field gel electrophoresis (PFGE) profiles was also performed. FTIRS was not only able to distinguish the strains of L. plantarum under different growth conditions but also to prove the phenotypic stability of L. plantarum type strain LP-CT after six growing steps. Regardless of the growth conditions, FTIRS spectra related to LP-CT constituted a unique hierarchical cluster, separated from the other L. plantarum strains. These results were confirmed by a PFGE analysis. In addition, based on FTIRS data, broth cultures demonstrated a higher reproducibility and discriminatory power with respect to agar ones. These results support the introduction of FTIRS in the probiotic industry, allowing for the step-by-step monitoring of massive microbial production while also guaranteeing the stability and purity of the probiotic strain. The proposed novel approach can constitute an impressive improvement in the probiotic manufacturing process.
- Published
- 2022
6. Intestinal microbiome: a new target for chalaziosis treatment in children?
- Author
-
Angela Amoruso, Roberto dell'Omo, Ilaria Paiano, Silvia Bartollino, Ciro Costagliola, Mariaelena Filippelli, Pasquale Napolitano, Marco Pane, Filippelli, Mariaelena, Dell’Omo, Roberto, Amoruso, Angela, Paiano, Ilaria, Pane, Marco, Napolitano, Pasquale, Bartollino, Silvia, and Costagliola, Ciro
- Subjects
medicine.medical_specialty ,Streptococcus thermophilus ,Pilot Projects ,law.invention ,Lesion ,03 medical and health sciences ,Probiotic ,0302 clinical medicine ,law ,030225 pediatrics ,Internal medicine ,Lactobacillus ,medicine ,Tobramycin ,Humans ,030212 general & internal medicine ,Microbiome ,Prospective Studies ,Child ,Dexamethasone ,biology ,business.industry ,Probiotics ,biology.organism_classification ,Gastrointestinal Microbiome ,Italy ,Pediatrics, Perinatology and Child Health ,Intestinal Microbiome ,medicine.symptom ,business ,medicine.drug - Abstract
Intestinal dysbiosis (changes in the gut commensal microbiome) is related to several ophthalmic diseases. The aim of this study was to verify whether oral specific probiotics can alter the clinical course of chalaziosis and its recurrence. A prospective comparative pilot study involving 26 children suffering from chalaziosis was conducted. Children were randomly divided into two groups. The first group received medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days), and the second group received medical treatment plus a daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10 (DSM 25246), ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02 (DSM 29536) and ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus (DSM 16606) with maltodextrin as the bulking agent (Probiotical S.p.A., Novara, Italy). All patients were evaluated at 2-week intervals for 3 months. If the lesion had not disappeared or decreased in size to 1 mm or less in diameter at the time of subsequent visits, the same procedure was repeated for another 3-month cycle. There was a significant difference in the time taken for complete resolution of the chalazion between the two groups in favour of the children receiving the probiotics. The treatment was not associated with any significant complications in either group. Trial registration: The trial was registered at clinical trials.gov under NCT04322500 on 25/03/2020 ("retrospectively registered").Conclusions: Modification of the intestinal microbiome with specific probiotics can alter the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis. Probiotic supplementation can increase the effectiveness of traditional therapies by prompting the complete resolution of chalaziosis in a shorter amount of time, in an easy and feasible way. What is Known: • The intestinal microbiome plays a crucial role in several inflammatory diseases of the eye and is considered a therapeutic target. • Probiotics play a role in the prevention and treatment of different conditions in children. What is New: • In children probiotic supplementation is safe and effective. • Probiotic supplementation reduced the time required for complete resolution of the chalazion.
- Published
- 2020
7. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies
- Author
-
Marco Pane, Nicole Bozzi Cionci, Diana Di Gioia, Letizia Mazzini, Luca Mogna, Angela Amoruso, Roberto Cantello, Francesca Gaggia, Fabiola De Marchi, Irene Aloisio, Ausiliatrice Lucenti, Enrica Bersano, Giovanni Mogna, Mazzini, Letizia, Mogna, Luca, De Marchi, Fabiola, Amoruso, Angela, Pane, Marco, Aloisio, Irene, Cionci, Nicole Bozzi, Gaggìa, Francesca, Lucenti, Ausiliatrice, Bersano, Enrica, Cantello, Roberto, Di Gioia, Diana, and Mogna, Giovanni
- Subjects
0301 basic medicine ,Adult ,Male ,Lactobacillus fermentum ,Colony Count, Microbial ,Gut flora ,Microbiology ,03 medical and health sciences ,Feces ,0302 clinical medicine ,Double-Blind Method ,Enterobacteriaceae ,Lactobacillus ,Yeasts ,medicine ,microbiota ,Escherichia coli ,Humans ,Bifidobacterium ,biology ,business.industry ,Lactobacillus salivarius ,Probiotics ,Amyotrophic Lateral Sclerosis ,Gastroenterology ,biology.organism_classification ,medicine.disease ,Gastrointestinal Microbiome ,Gastrointestinal Tract ,030104 developmental biology ,Phenotype ,Female ,ALS ,business ,Dysbiosis ,Bacteriotherapy ,030217 neurology & neurosurgery ,Lactobacillus plantarum ,probiotic - Abstract
Background Recent preclinical studies suggest that dysfunction of gastrointestinal tract may play a role in amyotrophic lateral sclerosis (ALS) pathogenesis through a modification of the gut microbiota brain axis. Our study is the first focused on microbiota analysis in ALS patients. Aim Our aim was to study the main human gut microbial groups and the overall microbial diversity in ALS and healthy subjects. Moreover we have examined the influence of a treatment with a specific bacteriotherapy composed of Lactobacillus strains (Lactobacillus fermentum, Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus salivarius) acting on the gastrointestinal barrier. Methods We enrolled 50 ALS patients and 50 healthy controls, matched for sex, age, and origin. Fecal samples were used for total genomic DNA extraction. Enterobacteria, Bifidobacterium spp., Lactobacillus spp., Clostridium sensu stricto, Escherichia coli and yeast were quantified using quantitative polymerase chain reaction approach. Denaturing gradient gel electrophoresis analyses were performed to investigate total eubacteria and yeasts populations. Patients were randomized to double-blind treatment either with microorganisms or placebo for 6 months and monitored for clinical progression and microbiota composition. Results The comparison between ALS subjects and healthy group revealed a variation in the intestinal microbial composition with a higher abundance of E. coli and enterobacteria and a low abundance of total yeast in patients. Polymerase chain reaction denaturing gradient gel electrophoresis analysis showed a cluster distinction between the bacterial profiles of ALS patients and the healthy subjects. The complexity of the profiles in both cases may indicate that a real dysbiosis status is not evident in the ALS patients although differences between healthy and patients exist. The effects of the progression of the disease and of the bacteriotherapy on the bacterial and yeast populations are currently in progress. Conclusions Our preliminary results confirm that there is a difference in the microbiota profile in ALS patients.
- Published
- 2018
8. Three-Month Feeding Integration With Bifidobacterium Strains Prevents Gastrointestinal Symptoms in Healthy Newborns
- Author
-
Irene Aloisio, Flavia Prodam, Enza Giglione, Nicole Bozzi Cionci, Arianna Solito, Simonetta Bellone, Loredana Baffoni, Luca Mogna, Marco Pane, Gianni Bona, Diana Di Gioia, Aloisio, Irene, Prodam, Flavia, Giglione, Enza, Bozzi Cionci, Nicole, Solito, Arianna, Bellone, Simonetta, Baffoni, Loredana, Mogna, Luca, Pane, Marco, Bona, Gianni, and Di Gioia, Diana
- Subjects
0301 basic medicine ,medicine.medical_specialty ,breastfeeding ,Endocrinology, Diabetes and Metabolism ,ved/biology.organism_classification_rank.species ,lcsh:TX341-641 ,bottle-feeding ,Breast milk ,Gut flora ,Bifidobacterium breve ,Gastroenterology ,law.invention ,03 medical and health sciences ,Probiotic ,0302 clinical medicine ,infant colic ,law ,Lactobacillus ,Internal medicine ,microbiota ,Medicine ,functional gastrointestinal disorders ,Adverse effect ,Feces ,Bifidobacterium ,Nutrition ,Original Research ,Nutrition and Dietetics ,biology ,ved/biology ,business.industry ,functional gastrointestinal disorder ,biology.organism_classification ,030104 developmental biology ,business ,lcsh:Nutrition. Foods and food supply ,030217 neurology & neurosurgery ,probiotic ,Food Science - Abstract
Infantile functional gastrointestinal disorders are common in the first months of life. Their pathogenesis remains unknown although evidences suggest multiple independent causes, including gut microbiota modifications. Feeding type, influencing the composition of intestinal microbiota, could play a significant role in the pathogenesis. Previous studies supported probiotic supplementation success against colics, however mainly Lactobacillus spp. were tested. The aim of this study was to evaluate the effectiveness against functional gastrointestinal disorders of a Bifidobacterium breve based probiotic formulation including in the study both breast-fed and bottle-fed subjects. Two hundred and sixty-eight newborns were enrolled within 15 days from birth. One hundred and fifty-five of them effectively entered the study and were randomized in probiotic and placebo group, receiving the formulation for 90 days. The probiotic formulation consists of a 1:1 mixture of 2 strains of B. breve prepared in an oily suspension and administered in a daily dosage of 5 drops containing 108 CFU of each strain. Absolute quantification of selected microbial groups in the faeces was performed using qPCR. Anthropometric data, daily diary minutes of crying, number of regurgitations, vomits and evacuations, and colour and consistency of stools were evaluated before and after treatment. The study confirmed the positive role of breast milk in influencing the counts of target microbial groups, in particular the bifidobacteria community. No adverse events upon probiotic administration were reported, suggesting the safety of the product in this regimen. B. breve counts increased significantly in all administered newborns (p < 0.02). The study demonstrates that a 3 months treatment with B. breve strains in healthy breast-fed newborns helps to prevent functional gastrointestinal disorders, in particular reducing 56% of daily vomit frequency (p < 0.03), decreasing 46.5% of daily evacuation over time (p < 0.03), and improving the stool consistency (type 6 at the Bristol Stool chart instead of type 5) in those at term (p < 0.0001). Moreover, a significant reduction (8.65 vs. 7.98 LogCFU/g of feces, p < 0.03) of B. fragilis in the bottle-fed group receiving the probiotic formulation was observed.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.